Innate Pharma IPHA
NASDAQ IPHA
$1.59 +0.05 (+3.25%)
As of: Nov 11, 2026 · 3:56 PM EST

Innate Pharma (IPHA) Operating Expenses (2019)

Updated

Innate Pharma (IPHA) recorded Operating Expenses of -$28.68 million in the quarter ended Jun 30, 2026, compared with -$34.28 million a year earlier.

Analysis

Innate Pharma (IPHA) Operating Expenses (2019) Analysis & Trends

On a TTM basis, Innate Pharma's Operating Expenses came in at -$212.93 million as of Jun 30, 2026; for the year ended Dec 31, 2025, it was -$71.19 million.

  • Across earlier years, Operating Expenses came in at -$77.6 million in the year ended Dec 31, 2024, -$80.38 million in the year ended Dec 31, 2023, -$121.31 million in the year ended Dec 31, 2022 and -$82.97 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Jun 30, 2026 is the highest quarterly Operating Expenses in data going back to the quarter ended Jun 30, 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 15.99 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 11.12 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 11.14 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 12.53 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.00 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 6.66 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 4.84 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 7.09 Bn
10 Innate Pharma 142.45 Mn -64.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 51.55 Mn
API Access

Innate Pharma Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-expenses&ticker=IPHA&period=max&api_key=YOUR_API_KEY